Drugs and deal making are a potent combination.

But, after a series of deals that include Actavis buying Warner Chilcott for $5bn and Valeant buying private equity-owned Bausch & Lomb for $8.7bn, bankers and investors shouldn't get hooked. For the first time in years, Big Pharma can find reasons to go it alone.